By 1999, preclinical studies underscored the ability of taxanes to increase cancer cell sensitivity to radiotherapy through the phosphorylation of Bcl-2, which induces G2/M arrest and apoptosis via a p53-independent pathway (41). Here, TP53 is linked to cancer.